Dr. Michael J. Liptay is a cardiovascular surgeon at Rush University Medical Center in Chicago, Illinois. He also serves as the leader of University Thoracic Surgeons, the most highly-trafficked minimally invasive thoracic surgery group in the Chicago area. His division also boasts the most experience with minimally invasive surgery techniques in the entire Midwest.
The main focus of Dr. Liptay’s research is the early detection, staging and prognosis of lung cancer. He is considered one of Chicago’s leading lung cancer experts and an innovator in the field of thoracic surgery. Currently, his team is working on a serum blood test for the detection of lung cancer. In addition to his work leading the Division of Thoracic Surgery at Rush University Medical Center, Dr. Liptay holds several other leadership positions at the university. He serves as vice-chairperson in the university’s Department of Cardiovascular-Thoracic Surgery, medical director of the Coleman Foundation Chest Tumor Clinic, and is an associate professor at the Rush Medical College.
Dr. Liptay is the author of more than 100 manuscripts, book chapters and scholarly reports and has delivered lectures to experts around the world about his cancer research. The main focus of Dr. Liptay’s research is the early detection, staging and prognosis of lung cancer. He is considered one of Chicago’s leading lung cancer experts and an innovator in the field of thoracic surgery. Recently, his team has been working on a serum blood test for the detection of lung cancer.
Main Speciality: Thoracic Surgery
Other Interests & Specialties: General cardiac/thoracic surgery, adult general thoracic surgery, minimally invasive thoracic surgery and thoracic surgical oncology, particularly lung removal surgeries.
Certifications, Awards & Accolades: American Board of Thoracic Surgery Certification in Thoracic and Cardiac Surgery, Regional Top Doctor, American Chemical Society Fellow, named Super Doc by Super Doctors program, named Checkbook Top Doc
Education & Experience:
- Residency for General Surgery at Washington University Barnes-Jewish Hospital
- Fellowship for Thoracic Surgery at Brigham and Women’s Hospital
- Medical degree at Northwestern University Feinberg School of Medicine
Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Annals Thoracic Surgery. November 2011;92(5):1805-11. doi: 10.1016/j.athoracsur.2011.06.058
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Annals Surgery. September 1996;224(3):288-194.
Neoadjuvant Chemoradiation for Clinically Advanced Non-Small Cell Lung Cancer: An Analysis of 233 Patients. Annals of Thoracic Oncology. March 2011;92(1):233-243. doi: 10.1016/j.athoracsur.2011.03.001
Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. February 2011;(71)2:186-190. doi: 10.1016/j.lungcan.2010.05.006
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. Journal of Thoracic Oncology. June 2011;6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c
- Mesothelioma Doctors
- Cancer Centers
- Treatment Near You
- Experimental Treatments
- Alternative Treatments
- Clinical Trials
- Caregiver Resources
- Treatment Costs